U.S. markets open in 18 minutes
  • S&P Futures

    4,411.75
    -26.25 (-0.59%)
     
  • Dow Futures

    34,472.00
    -172.00 (-0.50%)
     
  • Nasdaq Futures

    15,183.75
    -119.75 (-0.78%)
     
  • Russell 2000 Futures

    2,238.60
    -16.60 (-0.74%)
     
  • Crude Oil

    73.05
    -0.25 (-0.34%)
     
  • Gold

    1,744.60
    -5.20 (-0.30%)
     
  • Silver

    22.32
    -0.36 (-1.58%)
     
  • EUR/USD

    1.1711
    -0.0036 (-0.30%)
     
  • 10-Yr Bond

    1.4290
    +0.0190 (+1.35%)
     
  • Vix

    20.37
    -0.50 (-2.40%)
     
  • GBP/USD

    1.3663
    -0.0057 (-0.42%)
     
  • USD/JPY

    110.5840
    +0.2830 (+0.26%)
     
  • BTC-USD

    41,085.64
    -2,450.28 (-5.63%)
     
  • CMC Crypto 200

    1,019.39
    -89.53 (-8.07%)
     
  • FTSE 100

    7,048.95
    -29.40 (-0.42%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Mylan says Teva's stake buy violates U.S. anti-trust rules

A sign bearing the logo of Teva Pharmaceutical Industries is seen in its Jerusalem oral solid dosage plant (OSD) December 21, 2011. REUTERS/Ronen Zvulun

(Reuters) - Mylan NV (MYL.O) said Teva Pharmaceutical Industries Ltd (TEVA.TA) (TEVA.N), which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.

Teva disclosed a 1.35 percent stake in Mylan last week.

"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.(http://1.usa.gov/1Q0SxgC)

Mylan did not clarify which anti-trust rule Teva violated.

The two companies were not immediately available for comment.

Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)